FibroBiologics Inc (FBLG) Noticias

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by...

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a...

Form S-3 - Registration statement under Securities Act of 1933

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form POS AM - Post-Effective amendments for registration statement

Form EFFECT - Notice of Effectiveness